ANEUKOR LLC Competitors

Lonza is a pioneer and world leader in the CDMO industry, setting the pace with cutting-edge science, smart technology, and lean manufacturing. United by a common purpose, we turn our customers’ breakthrough innovations into viable therapies and manufacture the medicines of tomorrow. Founded in Switzerland in 1897, our company is the first and original CDMO, and today we are more dynamic, agile and forward-focused than ever before. As one of the largest Western CDMOs, we bring together a global team of around 18,500 colleagues across five continents to deliver comprehensive, integrated solutions for our customers' complex needs. For our customers and their patients, we bring quality, safety and reliability to bring life-enhancing and life-saving treatments to market at speed and at scale. For our colleagues, we strive to create a sense of belonging and inclusion where every person can thrive and bring their best.

ABOUT HEMCARE: HemaCare, a Charles River company, is a global leader in the supply and customization of human-derived biological products and services for biomedical research, drug discovery, and cellular therapy process development. Through our network of collection centers with access to an extensive recallable and reliable donor network, we provide clients with the cellular material they need for the development of the next generation of cell and gene therapies – including fresh and cryopreserved starting material and isolated cellular material derived from peripheral blood, bone marrow, and cord blood. Combined with Charles River’s integrated, early-stage portfolio of discovery, safety assessment, and manufacturing support services, we provide customers comprehensive solutions from discovery through commercialization. To learn more about our portfolio and services, visit www.hemacare.com. HEMACARE'S MISSION: Providing a best-in-class portfolio of high quality, customizable human cellular material and services to support drug discovery, scientific research, and cell therapy. HEMACARE'S VISION: Advancing drug discovery, scientific research, and cell therapy with the highest quality human cells.

Celerion, a leader in early clinical research, delivers Applied Translational Medicine. Celerion applies our expertise and experience to translating information gained in research discoveries, to knowledge of drug action and effect in humans to support early drug development decisions and the clinical pharmacology labeling of new medicines. With over 50 years of experience and 600 global clinic beds (including 24 in-hospital), Celerion conducts and analyzes First-in-Human, clinical proof-of-concept, cardiovascular safety (TQT, robust QT), ADME and NDA-enabling clinical pharmacology studies. Celerion provides expertise on modeling and simulation, study design, medical writing (protocols and reports), clinical data sciences, biostatistics, and PK/PD analysis as well as small and large molecule bioanalytical assays through clinical drug development. Regulatory, drug development and program management complement Celerion’s service offerings. Our operations are strategically located in: Lincoln, Nebraska (Corporate Headquarters) Philadelphia, Pennsylvania Phoenix, Arizona Belfast, Northern Ireland,UK Zurich, Switzerland Vienna, Austria Richmond, Virginia Montreal, Quebec, Canada For more information, visit: www.celerion.com